BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
Provided By PR Newswire
Last update: Oct 28, 2024
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
Read more at prnewswire.comNASDAQ:BCLI (2/21/2025, 8:02:56 PM)
1.73
-0.07 (-3.89%)
Find more stocks in the Stock Screener
